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Thirty-four human immunodeﬁciency virus (HIV) specialists from 16 countries contributed to this project,
whose primary aim was to provide guidance on the screening, diagnosis, and monitoring of bone disease in
HIV-infected patients. Four clinically important questions in bone disease management were identiﬁed, and
recommendations, based on literature review and expert opinion, were agreed upon. Risk of fragility fracture
should be assessed primarily using the Fracture Risk Assessment Tool (FRAX), without dual-energy X-ray ab-
sorptiometry (DXA), in all HIV-infected men aged 40–49 years and HIV-infected premenopausal women aged
≥40 years. DXA should be performed in men aged ≥50 years, postmenopausal women, patients with a history
of fragility fracture, patients receiving chronic glucocorticoid treatment, and patients at high risk of falls. In
resource-limited settings, FRAX without bone mineral density can be substituted for DXA. Guidelines for an-
tiretroviral therapy should be followed; adjustment should avoid tenofovir disoproxil fumarate or boosted pro-
tease inhibitors in at-risk patients. Dietary and lifestyle management strategies for high-risk patients should be
employed and antiosteoporosis treatment initiated.
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Patients with human immunodeﬁciency virus (HIV)
infection have a higher risk of low bone mineral density
(BMD) and fragility fracture than the general popula-
tion [1] (Supplementary References 1–6). It is unclear
whether HIV infection itself contributes to low BMD;
however, individuals with HIV have a high prevalence
of risk factors for low BMD, such as poor nutrition,
low body weight, high rates of tobacco and alcohol
use, and low vitamin D levels [1] (Supplementary Ref-
erences 7, 8). In addition, initiation of antiretroviral
therapy (ART) is associated with a 2%–6% reduction
in BMD during the ﬁrst 2 years of treatment, which var-
ies with the speciﬁc ART medications used [1] (Supple-
mentary Reference 9). Osteoporosis in these patients
may be associated with signiﬁcant long-term morbidity,
which is likely to increase as the HIV-infected popula-
tion ages (Supplementary References 10, 11).
The Osteo Renal Exchange program (OREP) was es-
tablished to provide guidance and recommendations on
the screening, diagnosis, monitoring, and management
of bone disease in patients with HIV. A complementary
article on the management of renal disease will be pub-
lished elsewhere.
METHODS
The OREP was conducted in several stages, described in
detail in Supplementary Data, Appendix 1. In brief, 4
questions regarding screening and management of
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bone disease of key clinical importance to healthcare providers
managing individuals with HIV infection were identiﬁed
(Table 1). Following a comprehensive literature search, practical
answers were drafted and agreement was reached through an es-
tablished consensus process (Supplementary References 12, 13).
Finally, a level of evidence and grade of recommendation (GOR)
was assigned to each statement, in accordance with the Oxford
Centre for Evidence-Based Medicine (CEBM) 2009 criteria
(Supplementary Reference 14).
RESULTS
Screening and Monitoring Individuals With HIV Infection at Risk
for Fragility Fracture
It is appropriate to assess the risk of fragility fracture and low
BMD in all HIV-infected adults. Patients with major risk factors
for fragility fracture, including (1) a previous history of fragility
fracture, (2) receipt of glucocorticoid treatment for >3 months
(≥5 mg of prednisone daily or equivalent), or (3) at high risk for
falls, should be evaluated with dual-energy X-ray absorptiome-
try (DXA; see below) (CEBM 2a, GOR B) [2, 3]. In patients
without major fracture risk factors, an age-speciﬁc evaluation
is appropriate (Figure 1).
Fracture Risk Assessment by Fracture Risk Assessment Tool
Patients without a major risk factor for fragility fracture, men
who are aged 40–49 years and premenopausal women aged
≥40 years should have their 10-year risk of fracture assessed
using the Fracture Risk Assessment Tool FRAX score without
BMD (Figure 1; Table 2) [4, 5], with risk assessment performed
every 2–3 years or when a new clinical risk factor develops
(CEBM 5) [2, 3]. FRAX gives a calculation of the 10-year prob-
ability of a major fracture (spine, forearm, proximal humerus,
or hip) or hip fracture alone and can be used with or without
BMD assessment (www.shef.ac.uk/FRAX/) (CEBM 2b, GOR
B) [6, 7].Risk factors used in the FRAX score are listed in Table 3
[6] (Supplementary References 15–26). As HIV infection and its
treatment are associated with an increased risk for low BMD
and fragility fracture (Supplementary References 1–6), some ex-
perts recommend the “secondary cause” of osteoporosis box
should be checked when the FRAX calculator tool is used
(CEBM 5) [1]. When calculating the FRAX score, country-
speciﬁc algorithms should be used; however, if these are not
available, another country with similar population characteris-
tics should be chosen as a surrogate (CEBM 1a, GOR A) (Sup-
plementary References 15, 16). FRAX can also be used to
identify HIV-infected patients who should be assessed with
DXA scanning for low BMD (CEBM 1a, GOR A) [6, 7].
DXA Screening
It is reasonable to assess BMD by DXA scans in (1) men aged
40–49 years or premenopausal women aged ≥40 years, who
have an intermediate- or high-risk stratiﬁcation by FRAX
(>10% 10-year risk of major osteoporotic fracture), (2) all post-
menopausal women, (3) all men ≥50 years of age, and (4) adults
with major fragility fracture risk factors regardless of age
(CEBM 1a, GOR A) [2]. In countries in which DXA scans are
not easily obtained, a DXA scan is not required to make treat-
ment decisions for patients with a high risk of fracture (eg,
FRAX score ≥20% for a 10-year risk of all osteoporotic frac-
ture). Routine DXA screening of all HIV-infected patients on
ART is not recommended.
When interpreting DXA scan results, T-scores should be
used for postmenopausal women and men ≥50 years of age,
and z scores used for those <50 years of age (CEBM 1a, GOR
A) [8, 9]. The T-score thresholds for diagnosis of osteopenia
and osteoporosis are shown in Table 4 [4, 8]; note that Z-scores
are not used to diagnose osteoporosis. The optimal interval be-
tween DXA scan screening (or FRAX assessment) is unknown.
Repeat DXA scanning should be considered after 1–2 years for
those with baseline advanced osteopenia (T-score, −2.00 to
−2.49) and after 5 years for mild to moderate osteopenia (T-
score, −1.01 to −1.99) (CEBM 2b, GOR B) [10, 11].The optimal
interval for rescreening is also unclear for patients with normal
BMD (T-score > −1) by DXA screening, although data from the
general population suggest an interval of up to 15 years [10].
Rescreening should be considered earlier in those who have a
new fragility fracture or develop a new major osteoporosis
risk factor (CEBM 5).
Vertebral Fracture Screening and Assessment
Subclinical vertebral fractures are common in HIV-infected in-
dividuals (prevalence of approximately 25%) (Supplementary
References 27, 28) and are a strong risk factor for future frac-
tures. Therefore, height should be measured every 1–2 years in
adults≥50 years of age (CEBM 5) [4].Assessment for subclinical
vertebral fractures using lateral radiographs of the lumbar and
thoracic spine or DXA-based vertebral fracture assessment is in-
dicated for women aged ≥70 years and all men aged ≥80 years if
Table 1. Key Clinical Questions Relating to Bone Disease That
Were Identiﬁed and Addressed During the Osteo Renal
Exchange Program
1 + 3a To identify HIV-infected patients at risk for fragility fracture,
what are the ideal screening, workup, and monitoring
strategies?
2 How should ART be managed in ART-naive and -experienced
patients at risk of bone disease?
4 What is the optimal strategy for the management of patients
at risk for fragility fracture?
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus.
a Questions 1 and 3 were combined.
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BMD T-score is <−1.0 at the spine, total hip, or femoral neck;
women aged 65–69 years, and men aged 75–79 years, if BMD
T-score is –1.5 or less; and postmenopausal women aged 50–
64 years and men aged 50–69 years with speciﬁc risk factors
such as fragility fracture, historical height loss of ≥4 cm (≥1.5
inches), prospective height loss of ≥2 cm (≥0.8 inches), or recent
or ongoing long-term glucocorticoid treatment (CEBM 5) [2, 4,
12–14] (Supplementary References 5, 27).
Figure 1. Algorithm for the screening, assessment, management, and monitoring of bone disease in human immunodeﬁciency virus (HIV)-infected pa-
tients. Abbreviations: BMD, bone mineral density; DXA, dual energy X-ray absorptiometry; FN, femoral neck; FRAX, Fracture Risk Assessment Tool; LS,
lumbar spine; TH, total hip.
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Laboratory and Biomarker Assessments
Laboratory tests are not indicated to determine fracture risk or
low BMD. Investigations for speciﬁc and reversible secondary
causes of osteoporosis or low BMD should be performed
(Table 5) [15]. Markers of bone turnover or inﬂammation
should not be routinely measured in clinical practice for the as-
sessment of bone disease or fracture risk, or at the time of ini-
tiation of ART (CEBM 2a, GOR D) [4, 16, 17].
Managing ART in ART-Naive and -Experienced Patients
As the beneﬁts of ART far outweigh the potential negative long-
term effects on bone mass and metabolism, and fracture risk,
local or national guidelines for initiation and choice of ART reg-
imen should be followed.
A discussion about alternative ART regimens should occur in
treatment-naive or -experienced individuals with low BMD or
osteoporosis (Figure 2). This will primarily involve the avoid-
ance of tenofovir disoproxil fumarate (TDF) or boosted prote-
ase inhibitors (PIs), as these regimens have been associated with
a greater decrease in BMD compared with other nucleoside re-
verse transcriptase inhibitors and raltegravir (Figure 2) (CEBM
5) [1] (Supplementary References 29–32). Novel antiretroviral
strategies such as a ritonavir-boosted PI plus raltegravir have
been associated with signiﬁcantly smaller changes in BMD
than a ritonavir-boosted PI plus TDF/emtricitabine regimen
(Supplementary References 29, 32, 33), but these strategies are
not recommended for initial therapy except in patients in whom
both TDF and abacavir are contraindicated (Supplementary
References 34). Dolutegravir plus abacavir/lamivudine is a rec-
ommended regimen; however, there are no published data on
the effects of dolutegravir on BMD.
Patients With Osteomalacia
Osteomalacia is deﬁned as softening of the bone caused by defec-
tive bone mineralization due to inadequate amounts of available
calcium and/or phosphorous and can lead to bone pain, muscle
weakness, low BMD, and fragility fracture. Among HIV-infected
patients, osteomalacia has been rarely associated with TDF or efa-
virenz treatment, due to effects on phosphorus homeostasis and
vitamin D metabolism, respectively (Supplementary References
32, 37). Osteomalacia should be suspected in a patient with
low BMD who has hypophosphatemia or phosphate wasting
(fractional excretion of phosphorus >20%–30%) or severe vita-
min D deﬁciency (generally a 25-hydroxy vitamin D level <10
ng/mL [25 nmol/L], accompanied by increases in parathyroid
hormone and alkaline phosphatase), and the use of TDF and/
or efavirenz should be avoided (CEBM 5).
Optimal Management Strategy for Patients at Risk for Fragility
Fracture
Basic Recommendations for All HIV-Infected Patients
Management strategies for patients at high risk for fragility
fracture (Figure 2) include dietary and lifestyle changes. An
Table 2. Interpretation of Fracture Risk Assessment Tool Scores
Fracture Risk Definition Management
Low <10% 10-year risk of major fracture Reassure and reassess in ≤5 y depending on the clinical context
Moderate/intermediate 10%–20% 10-year risk of major
osteoporotic fracture
Measure BMD and recalculate fracture risk to determine whether an
individual’s risk lies above or below the intervention threshold
High 10-year risk of major osteoporotic
fracture ≥20% and/or hip fracture
≥3%
Can be considered for treatment without the need for BMD, although
BMD measurement may sometimes be appropriate, particularly in
younger postmenopausal women
Source: [4, 5].
Abbreviation: BMD, bone mineral density.
Table 3. Essential Components of Patient History and
Examination Required for Fracture Risk Assessment Tool and
Assessment for Low Bone Mineral Density
Risk factors required for FRAX [6] (Supplementary References 15–24)
Age
Race/geographic location
Female sex
BMI/height and weight
Prior fragility fracture
Parental history of hip fracture
Current tobacco smoking
Alcohol ≥3 standard drinks per day
Long-term use of glucocorticoids (≥5 mg prednisone per day or
equivalent for >3 mo)
Rheumatoid arthritis
Secondary causes of osteoporosisa
Additional risk factors important for fracture risk assessment
Frailty/fall risk/physical inactivity (Supplementary Reference 25)
Vitamin D deficiency (Supplementary Reference 26)
Abbreviations: BMI, body mass index; FRAX, Fracture Risk Assessment Tool.
a Includes type I (insulin dependent) diabetes, osteogenesis imperfecta in
adults, untreated long-standing hyperthyroidism, hypogonadism or premature
menopause (<45 years of age), chronic malnutrition, or malabsorption and
chronic liver disease.
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adequate daily intake of dietary calcium is recommended for
postmenopausal women and men ≥50 years of age (CEBM 1,
GOR B) [1, 4, 5]. Daily total calcium intake should be 1000
mg for men 50–70 years of age, or 1200 mg for women ≥51
years of age and men ≥71 years of age (CEBM 1, GOR B)
[4].Dietary calcium should be increased as a ﬁrst-line approach,
but calcium supplements may be appropriate if dietary calcium
intake is insufﬁcient (CEBM 2b, GOR B) [18, 19].
As HIV-infected patients are at risk of vitamin D insufﬁcien-
cy or deﬁciency (CEBM 2b, GOR B) [20–24], vitamin D status
should be determined by serum 25-hydroxy vitamin D levels in
those with a history of low BMD and/or fracture (CEBM 1,
GOR B). Determination of vitamin D status may also be consid-
ered in patients with any of the major risk factors for low vita-
min D levels (eg, dark skin, dietary deﬁciency, avoidance of sun
exposure, malabsorption, obesity, chronic kidney disease, or
treatment with regimens containing efavirenz) (CEBM 2b,
GOR C) [2, 25–27] (Supplementary Reference 37), although
the health beneﬁt of identiﬁcation and correction of vitamin
D deﬁciency in these groups is unclear (CEBM 4, GOR D) [2].
Supplementary vitamin D should be given to HIV-infected
patients with vitamin D insufﬁciency (<20 ng/mL [<50 nmol/
L]) or deﬁciency (<10 ng/mL [<25 nmol/L]), particularly if
the deﬁciency is associated with compensatory hyperparathy-
roidism (CEBM 2b, GOR B) (Table 6) [1, 15, 28, 29] (Supple-
mentary Reference 10). Vitamin D intake should be titrated
to achieve a serum 25-hydroxy vitamin D level of approximately
30 ng/mL (75 nmol/L) and a suitable maintenance dose admin-
istered thereafter to sustain this level (CEBM 2a, GOR B) [4].
Vitamin D deﬁciency can blunt bone response to bisphospho-
nate treatment; therefore, the target serum 25-hydroxy vitamin
D level of 30 ng/mL should be achieved before initiating therapy
with an antiresorptive drug (CEBM 3a/b, GOR C) [30–32].
HIV-infected patients with osteopenia/osteoporosis should
be reminded to increase regular weight-bearing and muscle-
strengthening exercise, avoid tobacco use and excessive alcohol
intake, and take steps to prevent falls (CEBM 5) [33–36] (Sup-
plementary Reference 1).
Therapeutic Management of Osteoporosis in HIV-Infected
Patients
Anti-osteoporosis treatment should be initiated for HIV-infected
patients under the same criteria as those stated in country-/
region-speciﬁc guidelines for the general population (Figure 2)
(CEBM 2a, GOR C) [1, 28]. In the United States, for example,
this would include all patients at high risk for fracture, including
postmenopausal women and men ≥50 years of age presenting
with a hip or vertebral (clinical or morphometric) fracture; or a
Table 4. Bone Mineral Density T- and Z-Score Thresholds for Determination of Osteopenia and Osteoporosis
Population Interpretation: Use of T-Score or Z-Score Normal Osteopenia Osteoporosis
Postmenopausal women
and men ≥50 y of age
T-score (compared with a young healthy adult) ≥−1 SD Between −2.5 and −1 SD ≤ −2.5 SD
All others Z-score (age-, sex-, ethnicity-matched) Low BMD for chronological age if ≤ −2 SDa
Sources: [4, 8].
Abbreviations: BMD, bone mineral density; SD, standard deviation.
a In premenopausal women, men <50 years of age, and children, the diagnosis of osteoporosis should not be made by BMD criteria alone [4].
Table 5. Causes of Secondary Osteoporosis
Osteoporosis-Associated
Condition Laboratory Evaluation
Endocrine disorders
Vitamin D deficiencya 25-hydroxy vitamin D
Hyperparathyroidisma Intact parathyroid hormone, total
calcium, phosphate, albumin,
creatinine
Subclinical
hyperthyroidisma
Thyroid-stimulating hormone, free
thyroxine
Hypogonadisma Men: free testosterone with morning
measurement; women: menstrual
history, estradiol, follicle-stimulating
hormone, prolactin
Cushing syndrome 1 mg overnight dexamethasone
suppression test or late-evening
salivary cortisol levels
Renal disorders
Phosphate wastinga Simultaneous serum phosphate and
creatinine and spot urine phosphate
and creatinine to calculate fractional
excretion of phosphate
Idiopathic hypercalcuriaa 24-hour urinary calcium
Gastrointestinal disorders
Celiac sprue Immunoglobulin A tissue
transglutaminase antibody
Hematologic disorders
Multiple myeloma Complete blood count, serum protein
electrophoresis
Mastocytosis Serum tryptase
Source: [15].
a First-line evaluations that should be investigated in all patients with a history of
fracture, osteoporosis, or with 10-year risk of osteoporotic fracture by Fracture
Risk Assessement Tool≥20%. Other conditions should be investigated if other
clinical factors suggest that these disorders are present.
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T-score ≤−2.5 at the femoral neck or spine after appropriate
evaluation to exclude secondary causes of osteoporosis; or low
bone mass (T-score between −1.0 and −2.5 at the femoral neck
or spine) and a 10-year probability of a hip fracture ≥3% or
major osteoporosis-related fracture ≥20% based on FRAX
(CEBM 1, GOR B) [4].Treatment thresholds may vary by coun-
try depending on multiple factors, including differences in the
cost and availability of anti-osteoporosis treatment, the diag-
nostic resources available, and the costs associated with treating
fracture. Before initiating anti-osteoporosis treatment, second-
ary causes of low BMD should be evaluated (Table 5) (CEBM
2a, GOR C) [1, 15, 29, 37] (Supplementary Reference 10).
Avoidance or discontinuation of medications associated with
bone loss (eg, antiepileptic drugs, proton pump inhibitors,
thiazolidinediones, and corticosteroids) should be considered
if appropriate alternatives are available (CEBM 5).
Alendronate or zoledronic acid is recommended for HIV-
infected patients with osteoporosis (CEBM 2b, GOR A) [37–44]
(Supplementary Reference 10). Other bisphosphonates have not
been evaluated in this patient group. Patients with HIV infec-
tion should receive alendronate 70 mg once weekly (with calci-
um carbonate 1000 mg/vitamin D 400 IU per day) (CEBM 2a,
GOR B) [37]. Intravenous zoledronic acid 5 mg yearly can be
given as an alternative to alendronate.
Treatment duration should be individualized [4]. Bisphos-
phonate treatment should be reviewed after an initial 3- to
5-year period, because of concerns about the negative effects
of long-term suppression of bone turnover (such as osteonecro-
sis of the jaw and atypical femoral fractures) (CEBM 1, GOR B)
[4, 10]. Several outcomes have been used in the general popula-
tion to judge the success of anti-osteoporosis treatment, includ-
ing the lack of deﬁnite fractures, or symptoms or signs of
possible fracture; maintenance of height (<1 cm of loss)
(CEBM 2b, GOR C) [45]; no change or an increase in BMD
measured by central DXA of hip and spine (CEBM 1, GOR
B) [46]; reduction in serum or urine markers of bone resorption
of ≥30% (CEBM 2b, GOR B) [47–50]; and therapy adherence
(CEBM 2b, GOR B) [47, 51–55].
Figure 2. Algorithm for the management of antiretroviral therapy in HIV-infected patients at risk of bone disease. Abbreviations: ART, antiretroviral ther-
apy; BMD, bone mineral density; DF, disoproxil fumarate; FRAX, Fracture Risk Assessment Tool; HIV, human immunodeﬁciency virus; PI, protease inhibitor.
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In HIV-infected patients, if BMD continues to decline on oral
bisphosphonate therapy, a second-line approach can include in-
travenous zoledronic acid (CEBM 2b, GOR C) [40, 42, 43, 56].
Teriparatide may also be considered in this setting, but data are
limited in HIV-infected populations (CEBM 4, GOR D) [57].
The safety and efﬁcacy of denosumab has not been evaluated
in HIV-infected individuals (CEBM 5). Referral to a specialist
may be necessary in cases of treatment intolerance or failure
or in cases of suspected osteomalacia (CEBM 2b, GOR C) [1].
DISCUSSION
This consensus-based, evidence-driven process was designed to
develop and consolidate practical guidance for the screening, di-
agnosis, monitoring, and treatment of bone disease in HIV. The
pathogenesis of bone disease in HIV infection has not been
clearly deﬁned, and is likely to be multifactorial. In addition
to traditional osteoporosis risk factors, accumulating evidence
supports the role of ART as an important factor associated
with signiﬁcant loss of BMD. Although the majority of random-
ized studies have reported reductions in BMD after initiation of
ART, it appears that ART regimens that include TDF and/or ri-
tonavir-boosted PIs are associated with a signiﬁcantly greater
loss of BMD, and these observations are reﬂected in our
recommendations.
The optimal HIV-infected population to undergo DXA
screening for low BMD has not been clearly established. Access
to screening will also vary according to country-speciﬁc DXA
screening guidelines for the general population. Alternative rec-
ommendations for DXA screening in HIV populations have
been provided in this guidance, based on the ease of obtaining
DXA.
The guidance provided in this publication differs from some
of the other guidelines for the screening and management of
bone disease in HIV infection, especially with regard to ART
regimen choice and options for switching regimens [1, 2, 13].
Similar to the most recent 2014 European AIDS Clinical Society
(EACS) guidelines [2], we make speciﬁc recommendations re-
garding the avoidance of ART therapies that have speciﬁc skel-
etal effects, including TDF and boosted PIs, in patients at risk
for fragility fracture. Our recommendations are restricted to
available evidence from clinical trials examining BMD changes;
the ﬁndings of studies assessing the role of speciﬁc antiretroviral
drugs in bone fractures have been inconsistent (Supplementary
References 46, 47). Among integrase inhibitors, there are only
limited data on the effect of dolutegravir and elvitegravir on
bone, whereas there are data to support the use of raltegravir
for its “bone-friendly” proﬁle (Supplementary Reference 48).
Well-designed trials are needed to fully determine the effect
of integrase inhibitors when used as initial therapy or after a
switch. Other knowledge gaps identiﬁed by this project are de-
tailed in the Supplementary Data.
Our recommendations differ in several ways from the 2014
EACS guidelines. First, in our screening recommendations, we
base the need for DXA evaluation on the results of the FRAX
algorithm for those who are aged 40–49 years and do not
meet other criteria for screening. This provides clear guidance
to clinicians to assess fracture risk in persons in this younger age
group, who are generally at low absolute risk of fracture. Also, in
contrast to the EACS guidelines, men with clinical hypogonad-
ism are not identiﬁed as a speciﬁc risk group in whom DXA
screening should be targeted. The vast majority of these men
will be eligible for screening based on their inclusion in other
risk groups. Next, clinicians from 16 different countries partic-
ipated in the program and provided input into these recom-
mendations. Given the variation of practice around the
world regarding osteoporosis screening and treatment in the
general population, it is difﬁcult to arrive at one set of recom-
mendations for metabolic bone disease in HIV-infected per-
sons that are applicable in all countries. With the use of
FRAX without BMD, we emphasize that fracture risk can be
assessed even in resource-limited settings. Finally, while we
generally concur with the 2014 EACS guidelines, our recom-
mendations are fully referenced with the underlying evidence
base graded.
The OREP has several limitations. First, although literature
searches were based on carefully constructed, formalized key-
word strings, the review of the literature does not meet strict cri-
teria for a systematic review. Second, the OREP did not address
Table 6. Vitamin D Supplementation Regimensa
Vitamin D Level Supplementation Regimen
>30 ng/mL (75 nmol/L) 1000 IU/day vitamin D3 (cholecalciferol)
20–30 ng/mL
(50–75 nmol/L)
(insufficiency)
2000 IU/day vitamin D3
15–19 ng/mL (37.5–50
nmol/L) (deficiency)
Vitamin D2 (ergocalciferol) or D3 50 000
IU/week × 8 weeks (or equivalent of
6000 IU/day vitamin D3)b
Maintenance: vitamin D3 2000 IU/dayc
<15 ng/mL (37.5 mmol/L)
(severe deficiency)
Vitamin D2 or D3 50 000 IU once
weekly × 8–12 wk (or equivalent of
6000 IU/day vitamin D3)b
Maintenance: vitamin D3 2000 IU/dayc
Source: [15].
a Well-designed trials investigating the effects of calcium and vitamin D on
bone mineral density in human immunodeficiency virus–positive individuals
are still lacking.
b Consider a more aggressive replacement strategy if patient has secondary
hyperparathyroidism, osteomalacia, malabsorption syndrome, or obesity or is
taking medications that affect vitamin D metabolism.
c Recheck 25-hydroxy vitamin D level after course of ergocalciferol, with a goal
of >30 ng/mL. Consider monitoring urinary calcium in patients with a history of
nephrolithiasis and concurrent calcium supplementation.
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all aspects of the management of bone diseases in HIV-infected
patients. Instead, questions were prioritized to provide the most
clinically useful guidance. Finally, the guidance does not take
into account differing resource settings, and it may not be pos-
sible for all physicians to apply all aspects of the guidance within
their practice.
Nonetheless, the OREP followed an academically rigorous
process, supported by a group of leading physicians that repre-
sented a broad range of clinical opinion from diverse geograph-
ic regions and a variety of clinical practices. As such, it provides
evidence-based guidance on the screening, monitoring, and
treatment of bone disease in HIV-infected patients that is of
practical use in clinical settings.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
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